A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populations.

Health services research Implementation science Population-based genomic screening

Journal

Implementation science communications
ISSN: 2662-2211
Titre abrégé: Implement Sci Commun
Pays: England
ID NLM: 101764360

Informations de publication

Date de publication:
28 Apr 2022
Historique:
received: 07 02 2022
accepted: 20 03 2022
entrez: 28 4 2022
pubmed: 29 4 2022
medline: 29 4 2022
Statut: epublish

Résumé

In 2021, the Medical University of South Carolina (MUSC) partnered with Helix, a population genetic testing company, to offer population-wide genomic screening for Centers for Disease Control and Preventions' Tier 1 conditions of hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia to 100,000 individuals in South Carolina. We developed an implementation science protocol to study the multi-level factors that influence the successful implementation of the In Our DNA SC initiative. We will use a convergent parallel mixed-methods study design to evaluate the implementation of planned strategies and associated outcomes for In Our DNA SC. Aims focus on monitoring participation to ensure engagement of diverse populations, assessing contextual factors that influence implementation in community and clinical settings, describing the implementation team's facilitators and barriers, and tracking program adaptations. We report details about each data collection tool and analyses planned, including surveys, interview guides, and tracking logs to capture and code work group meetings, adaptations, and technical assistance needs. The goal of In Our DNA SC is to provide population-level screening for actionable genetic conditions and to foster ongoing translational research. The use of implementation science can help better understand how to support the success of In Our DNA SC, identify barriers and facilitators to program implementation, and can ensure the sustainability of population-level genetic testing. The model-based components of our implementation science protocol can support the identification of best practices to streamline the expansion of similar population genomics programs at other institutions.

Sections du résumé

BACKGROUND BACKGROUND
In 2021, the Medical University of South Carolina (MUSC) partnered with Helix, a population genetic testing company, to offer population-wide genomic screening for Centers for Disease Control and Preventions' Tier 1 conditions of hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemia to 100,000 individuals in South Carolina. We developed an implementation science protocol to study the multi-level factors that influence the successful implementation of the In Our DNA SC initiative.
METHODS METHODS
We will use a convergent parallel mixed-methods study design to evaluate the implementation of planned strategies and associated outcomes for In Our DNA SC. Aims focus on monitoring participation to ensure engagement of diverse populations, assessing contextual factors that influence implementation in community and clinical settings, describing the implementation team's facilitators and barriers, and tracking program adaptations. We report details about each data collection tool and analyses planned, including surveys, interview guides, and tracking logs to capture and code work group meetings, adaptations, and technical assistance needs.
DISCUSSION CONCLUSIONS
The goal of In Our DNA SC is to provide population-level screening for actionable genetic conditions and to foster ongoing translational research. The use of implementation science can help better understand how to support the success of In Our DNA SC, identify barriers and facilitators to program implementation, and can ensure the sustainability of population-level genetic testing. The model-based components of our implementation science protocol can support the identification of best practices to streamline the expansion of similar population genomics programs at other institutions.

Identifiants

pubmed: 35484601
doi: 10.1186/s43058-022-00286-2
pii: 10.1186/s43058-022-00286-2
pmc: PMC9052691
doi:

Types de publication

Journal Article

Langues

eng

Pagination

48

Subventions

Organisme : NCI NIH HHS
ID : K00 CA253576
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210962
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210963
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Genet Med. 2011 Jan;13(1):21-5
pubmed: 21057319
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
Genet Med. 2020 Nov;22(11):1874-1882
pubmed: 32601386
Implement Sci. 2020 Sep 25;15(1):84
pubmed: 32988389
Health Aff (Millwood). 2016 Aug 1;35(8):1367-73
pubmed: 27503959
Implement Sci. 2021 Jul 2;16(1):67
pubmed: 34215286
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
JAMA. 2016 May 10;315(18):1941-2
pubmed: 27163980
J Gen Intern Med. 2004 Mar;19(3):273-80
pubmed: 15009784
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10
pubmed: 25192939
Genome Med. 2021 Feb 5;13(1):17
pubmed: 33546753
Am J Prev Med. 2012 Sep;43(3):337-50
pubmed: 22898128
Am J Prev Med. 2018 Sep;55(3):422-430
pubmed: 30033029
Am J Epidemiol. 2004 Sep 1;160(5):407-20
pubmed: 15321837
Cancer Discov. 2018 Jul;8(7):803-811
pubmed: 29907587
Public Health Rev. 2018 Feb 21;39:4
pubmed: 29484218
Psychiatry Res. 2019 Oct;280:112513
pubmed: 31434011
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Behav Ther. 2018 Jul;49(4):525-537
pubmed: 29937255
Implement Sci. 2019 Feb 1;14(1):11
pubmed: 30709368
Implement Sci. 2021 Jul 13;16(1):71
pubmed: 34256763
Clin Transl Sci. 2012 Feb;5(1):48-55
pubmed: 22376257
Acad Med. 2000 Aug;75(8):850-2
pubmed: 10965867
Genet Med. 2017 Aug;19(8):858-863
pubmed: 28079898
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):404-412
pubmed: 27799157
JAMA Netw Open. 2018 Sep 7;1(5):e182140
pubmed: 30646163
Front Oncol. 2016 May 13;6:120
pubmed: 27242960
NPJ Genom Med. 2021 Apr 14;6(1):28
pubmed: 33854068
Genet Med. 2018 Jun;20(6):574-582
pubmed: 29240076
Front Public Health. 2018 Apr 09;6:102
pubmed: 29686983
Health Res Policy Syst. 2017 Feb 23;15(1):15
pubmed: 28231801

Auteurs

Caitlin G Allen (CG)

Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. allencat@musc.edu.

Daniel P Judge (DP)

Division of Cardiology, Medical University of South Carolina, Charleston, SC, USA.

Elissa Levin (E)

Clinical & Policy, Helix, San Mateo, CA, USA.

Katherine Sterba (K)

Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

Kelly Hunt (K)

Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

Paula S Ramos (PS)

Department of Medicine, Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

Cathy Melvin (C)

Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

Karen Wager (K)

Department of Healthcare Leadership and Management, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.

Kenneth Catchpole (K)

Anesthesia & Perioperative Medicine, Medical University of South Carolina, Charleston, SC, USA.

Catherine Clinton (C)

Clinical & Policy, Helix, San Mateo, CA, USA.

Marvella Ford (M)

Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.

Lori L McMahon (LL)

Office of Vice President for Research, Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.

Leslie Lenert (L)

Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, USA.

Classifications MeSH